CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 448 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $94,437,187 | -15.4% | 1,748,513 | +6.8% | 0.00% | 0.0% |
Q1 2024 | $111,564,220 | +12.0% | 1,636,799 | +2.9% | 0.00% | 0.0% |
Q4 2023 | $99,574,752 | +42.6% | 1,590,651 | +3.4% | 0.00% | 0.0% |
Q3 2023 | $69,842,729 | -18.7% | 1,538,725 | +0.5% | 0.00% | 0.0% |
Q2 2023 | $85,955,392 | +28.0% | 1,531,090 | +3.1% | 0.00% | 0.0% |
Q1 2023 | $67,147,056 | +14.5% | 1,484,569 | +2.9% | 0.00% | 0.0% |
Q4 2022 | $58,628,560 | -37.5% | 1,442,277 | +0.5% | 0.00% | -33.3% |
Q3 2022 | $93,803,000 | +16.7% | 1,435,410 | +8.5% | 0.00% | +50.0% |
Q2 2022 | $80,407,000 | +5.2% | 1,323,141 | +8.7% | 0.00% | 0.0% |
Q1 2022 | $76,410,000 | +199.4% | 1,217,289 | +261.4% | 0.00% | +100.0% |
Q4 2021 | $25,525,000 | -36.7% | 336,826 | -6.6% | 0.00% | 0.0% |
Q3 2021 | $40,355,000 | -5.5% | 360,541 | +36.7% | 0.00% | 0.0% |
Q2 2021 | $42,700,000 | +34.9% | 263,758 | +1.6% | 0.00% | 0.0% |
Q1 2021 | $31,643,000 | -17.4% | 259,697 | +3.8% | 0.00% | 0.0% |
Q4 2020 | $38,299,000 | +17.3% | 250,140 | -35.9% | 0.00% | 0.0% |
Q3 2020 | $32,655,000 | +33.2% | 390,424 | +17.0% | 0.00% | 0.0% |
Q2 2020 | $24,513,000 | +211.1% | 333,554 | +79.6% | 0.00% | – |
Q1 2020 | $7,879,000 | -24.0% | 185,772 | +9.2% | 0.00% | – |
Q4 2019 | $10,362,000 | +207.9% | 170,135 | +107.3% | 0.00% | – |
Q3 2019 | $3,365,000 | -12.0% | 82,091 | +1.1% | 0.00% | – |
Q2 2019 | $3,822,000 | +66.3% | 81,159 | +26.1% | 0.00% | – |
Q1 2019 | $2,298,000 | +33.9% | 64,338 | +7.1% | 0.00% | – |
Q4 2018 | $1,716,000 | -25.6% | 60,055 | +15.4% | 0.00% | – |
Q3 2018 | $2,307,000 | -19.6% | 52,023 | +6.6% | 0.00% | – |
Q2 2018 | $2,869,000 | +51.8% | 48,823 | +18.1% | 0.00% | – |
Q1 2018 | $1,890,000 | +366.7% | 41,344 | +139.4% | 0.00% | – |
Q4 2017 | $405,000 | +31.1% | 17,268 | -0.1% | 0.00% | – |
Q3 2017 | $309,000 | +13.2% | 17,283 | +1.6% | 0.00% | – |
Q2 2017 | $273,000 | – | 17,019 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |